Media coverage
103
Media coverage
Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet PR Newswire Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202926946&p=1gw&v=1&x=6wAym2ASxDpe-ENiehQisw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet Morningstar.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202939899&p=1gw&v=1&x=vywsE6F64JNeN3R-sgX4dQ Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet PR Newswire European (Top News) Country/Territory United Kingdom Date 9/03/23 Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet Street Insider Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202899521&p=1gw&v=1&x=IYg0P5Sjxmxy5KGNIyr-7w Persons Rajwanth Veluswamy Title Bergenbio Announces First Patient Dosed In Phase 1B/2A Trial Evaluating Bemcentinib In 1St Line Non-Small Cell Lung Cancer With STK11 Mutations Media name/outlet MENAFN -Press Releases (English) Country/Territory Jordan Date 9/03/23 Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet BioSpace Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203543291&p=1gw&v=1&x=b4cr9d5eND2vPj9u9NfHXw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet InvestorsObserver Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202918468&p=1gw&v=1&x=EE7HzJmmYT03N0VzqpYang Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet Finanzen.net Country/Territory Germany Date 9/03/23 URL ct.moreover.com/?a=50202918897&p=1gw&v=1&x=tQu18CacBFREwEXJwW2AZQ Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung.. Media name/outlet ADVFN UK Country/Territory United Kingdom Date 9/03/23 URL ct.moreover.com/?a=50202892734&p=1gw&v=1&x=yHRu_5nT1nheTjaUK51CQQ Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet Yahoo! Finanzas Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202926451&p=1gw&v=1&x=KKE10xSMr3QOErk694SP_Q Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet ADVFN UK Country/Territory United Kingdom Date 9/03/23 URL ct.moreover.com/?a=50202928805&p=1gw&v=1&x=S5iiHNt2sFuQuLmuUKONBQ Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet Yahoo! Finance Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202932065&p=1gw&v=1&x=RBe8fets2IYLGW8kgTtHhQ Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet ProfitQuotes.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202896752&p=1gw&v=1&x=jK3uuFU6QwOs72uN1QL-4Q Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet TickerTech.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202906072&p=1gw&v=1&x=T0WGBY3_Q2dj6abSLth7qw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet ADVFN US Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202922852&p=1gw&v=1&x=ARLIbqdSgd537v_TYo49AA Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet TD Ameritrade Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202926952&p=1gw&v=1&x=AOKQ219FSnoHmiVj078-bg Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11... Media name/outlet Greenville Business Magazine Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203030505&p=1gw&v=1&x=RawgUHF6koRDgmy6pZrkAA Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet Spoke.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203231230&p=1gw&v=1&x=AxRDYFz4iU_F3RzjcKqURg Persons Rajwanth Veluswamy Title BerGenBio ASA: BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet FinanzNachrichten.de Country/Territory Germany Date 9/03/23 URL ct.moreover.com/?a=50202932936&p=1gw&v=1&x=A0SOHNWVg3wZGAyjnx_WAg Persons Rajwanth Veluswamy Title BerGenBio: BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations (Millistream) Media name/outlet Avanza Bank AB Country/Territory Sweden Date 9/03/23 URL ct.moreover.com/?a=50202914481&p=1gw&v=1&x=6oCtRl6_Alz9ix4vA9t-Bg Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11... Media name/outlet Holliston - Local Town Pages Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202916740&p=1gw&v=1&x=HNsjVQByqBdBobrzzzMl3g Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Media name/outlet Times of San Diego Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202921452&p=1gw&v=1&x=yJ1nvDNabEqDc2ANjw2tAg Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet Cision News Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202922451&p=1gw&v=1&x=VlNDfG7oqlESNiBmQBNZVg Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Media name/outlet BluegrassLive.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202927049&p=1gw&v=1&x=nvCQ-HpuBHiGc2PkeY0O9w Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11... Media name/outlet Norwood - Local Town Pages Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202928346&p=1gw&v=1&x=7iAN2a8YeJZDjXpYH-RhBA Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11... Media name/outlet TheTidewaterNews.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202929780&p=1gw&v=1&x=IgT74TBg_a_2QkwSOrL-Mw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11... Media name/outlet Salisbury Post Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202931605&p=1gw&v=1&x=lamm4gMufQVVJY_60HHmAQ Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Media name/outlet Port Arthur News Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202932762&p=1gw&v=1&x=0XV9Sbozic4QksXDdaD3aQ Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Media name/outlet Elizabethton.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202939880&p=1gw&v=1&x=4-8o9wnTjF3p3fz9GbxJdg Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Media name/outlet LaGrange Daily News Country/Territory Georgia Date 9/03/23 URL ct.moreover.com/?a=50202941167&p=1gw&v=1&x=2GPp76u4HfLovjDpWoGfiA Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Media name/outlet Tryon Daily Bulletin Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202944986&p=1gw&v=1&x=78wjRA9FsHFbYZokFqK4_w Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11... Media name/outlet L' Observateur Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202948366&p=1gw&v=1&x=rdzqdeJ95IDiMS6a_xRzAg Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Media name/outlet Smithfield Times Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202951401&p=1gw&v=1&x=3mMqEAMfBtXKxKA1-ADPIw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Media name/outlet Jessamine Journal Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202953537&p=1gw&v=1&x=oo5C2VOoOL8Ozp_oVRgeGw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Media name/outlet Suffolk News Herald Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202954487&p=1gw&v=1&x=HH0Bu1cBmjsxA1U0L4-YaA Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11... Media name/outlet Kenbridge Victoria Dispatch Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202956535&p=1gw&v=1&x=gq4gf5t9bV9ZdSO0ulC-ig Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11... Media name/outlet Luverne Journal Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202962909&p=1gw&v=1&x=doFstsCUUbzZsHspWENzIA Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11... Media name/outlet Riverton Journal Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202968534&p=1gw&v=1&x=N5YyNgqgIQtiX1vnTc-GFw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11... Media name/outlet Ashland - Local Town Pages Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202968546&p=1gw&v=1&x=hS4UHjCTgMbXSbSCoHTmgw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11... Media name/outlet NorfolkWrentham - Local Town Pages Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202971146&p=1gw&v=1&x=XwDQ7Z9KFXGcosz8mRA7Ow Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet FOX 59 Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202972310&p=1gw&v=1&x=bi9WKhqAZ3NFsmgHnUPS1g Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet PIX11 Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202974421&p=1gw&v=1&x=TeTTFcPj7xDJi2nKpKMuDw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11... Media name/outlet Franklin- Local Town Pages Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202974946&p=1gw&v=1&x=tRbLtvotkwA1yK1GWLIClQ Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11... Media name/outlet Hopedale - Local Town Pages Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202987735&p=1gw&v=1&x=_cLOmu2EeuQEz-KJ99kE_g Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Media name/outlet Winchester Sun Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202988101&p=1gw&v=1&x=KkiSoeE7AX5rQHCGEO95Ow Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11... Media name/outlet Gates County Index Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203007044&p=1gw&v=1&x=i085mmpAhsXoPphX_Ujdew Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11... Media name/outlet Leesville Leader Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203020501&p=1gw&v=1&x=-VcvK4YaXJXyLWMr_J6A3Q Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Media name/outlet MillisMedway - Local Town Pages Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203023170&p=1gw&v=1&x=RuHvqACCCTuJyrlsTbu_qw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WGN-TV Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203026107&p=1gw&v=1&x=17JcU7i1KjbN8tZtDw-Xqw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet Wood TV Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203030305&p=1gw&v=1&x=62jLr_W-vgIWWKoFTY-2Uw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11... Media name/outlet Clemmons Courier Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203030964&p=1gw&v=1&x=IU85uEGI2VuEoNqBKQ8nSw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet Fox 4 WDAF TV Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203045420&p=1gw&v=1&x=xegeR65udb-XqS8a_0lgZQ Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet Valleycentral.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203048328&p=1gw&v=1&x=iFWf79q8iqz59YTh5DSOtQ Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WYTV News Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203051622&p=1gw&v=1&x=UdDkBCWZV9V4bsSYnSEKkw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet KNWA Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203056626&p=1gw&v=1&x=uRY2IoCABrQ8vmYB5P6YIQ Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WPRI Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203058290&p=1gw&v=1&x=rPuOLj6u_8EMzHnxfSCZ2Q Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WVNS Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203060408&p=1gw&v=1&x=Q0Z-Gg-pT9KM8T0MaMUoYw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WTVW FOX 7 Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203068162&p=1gw&v=1&x=6dQKUFfzhQFaPE6SGdzZAg Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WGNO Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203071011&p=1gw&v=1&x=9_dQbPGcPatb1fxBSI1Sog Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WHNT-TV Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203074166&p=1gw&v=1&x=Qq3Y58DB8LADducPuRgPWg Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet YourCentralValley.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203077671&p=1gw&v=1&x=isWbFq_-KSVmCC3-8WFdwA Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WREG Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203082359&p=1gw&v=1&x=YNrPUyPaY5xyvj09CU-ZWg Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet KTSM.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203086803&p=1gw&v=1&x=LAiOUGROXNYQIdEINDUNNQ Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WJMN Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203086814&p=1gw&v=1&x=OX8rdHFDd7F8DstpEBO3Yw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WYZZ-TV Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203086900&p=1gw&v=1&x=iy9BMVAMUwsyFJHtqCzm7w Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet KELOLAND TV Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203089523&p=1gw&v=1&x=-7X0IlRp9Mxdun__bIACWQ Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet OzarksFirst.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203089666&p=1gw&v=1&x=TJOukW3T_e7ev1YatsNlUw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WATE Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203089815&p=1gw&v=1&x=vX8SU6ljROtYdRCM5o3Mmw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet CNYHomepage.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203090830&p=1gw&v=1&x=-Ps0EMTVxbpiiAPKnsl7rA Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WTen.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203092549&p=1gw&v=1&x=h5cYjiOBWMjeypcXjOjlvw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet KODE TV Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203098202&p=1gw&v=1&x=kEiTFzsqy0r3Oe3efvvnDg Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet NBC4 Columbus Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203100397&p=1gw&v=1&x=zauRJei25xS47bla7yJIWw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet LocalSRY.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203102268&p=1gw&v=1&x=0LlX13L0Ow13IhskxVBMEg Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet KRQE Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203103931&p=1gw&v=1&x=QkvJ0WWtJWmCIOeO3o943Q Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet ConchoValleyHomepage.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203107062&p=1gw&v=1&x=VgR-KL3qX7fkcESfE7RKQg Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WKBN 27 First News Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203111771&p=1gw&v=1&x=F3WrTefKBTXGIVOPNSCJmw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WTRF Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203113425&p=1gw&v=1&x=aUTxABfPLNLFlSI2e_Y6jw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet Rochesterfirst.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203122218&p=1gw&v=1&x=UlZJiDzL4sZ2nSFNdJVvwg Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet MyStateLine.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203122230&p=1gw&v=1&x=vpwsNfvLBd8NsYY1B79Wjw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet FOX5 San Diego Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203128330&p=1gw&v=1&x=SnpgjN04SMKBe6DjpE_rNw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet YOUR BASIN Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203137266&p=1gw&v=1&x=0zk56FQiv_gA2QxCYKJ6ig Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet CW33 NewsFix Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203138558&p=1gw&v=1&x=tdvN4Xy1j9fDUmOcN8nK3g Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet CW39 NewsFix Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203140469&p=1gw&v=1&x=H1yj8kW9vEwDTg54zYrypA Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WSPA.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203155347&p=1gw&v=1&x=DuF8cAkESqKrgGuxqXRdtw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet KGET Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203157048&p=1gw&v=1&x=SyggyvFZkw5F6FqYUM3yAQ Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WBTW News13 Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203162582&p=1gw&v=1&x=TdXWjYtv7d6cOm2PJvT5eg Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WIAT TV Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203167760&p=1gw&v=1&x=LG7UQUeOrMZUSk3RdAe8Vw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WesternSlopeNow.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203168443&p=1gw&v=1&x=LMVzhKVGQyKils9WD3ojHg Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WDTN Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203168888&p=1gw&v=1&x=-ugDk06igcLcM5mKlryf-w Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet Wavy Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203171271&p=1gw&v=1&x=GX_JF47a0lcUiv94AH8KeA Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet ABC 27 Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203173116&p=1gw&v=1&x=DjZhTfmFKXYKUrslcpq4Qg Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet FOX 31 News KDVR Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203196618&p=1gw&v=1&x=AaxIOaG0KLrkdQWhSz4DjA Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet Myarklamiss.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203198323&p=1gw&v=1&x=H5LwBQRd1Tzl0Ln71qSitw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WNTZ Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203205535&p=1gw&v=1&x=T5r4ROSyaUZN7yNJ4_2IIA Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet KFOR.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203207680&p=1gw&v=1&x=IUnMT_r1FUur298nrs6tbA Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet Texomashomepage.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203220752&p=1gw&v=1&x=uDm7OHqazWv3f8Rglwp-TQ Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet 8 News Now Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203221719&p=1gw&v=1&x=Byt-5d0AYYgrDxLWZdor2A Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet CBS4Indy Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203248079&p=1gw&v=1&x=bAfOGA2X6Ktvs8vwzVeyTg Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WKRG Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203261422&p=1gw&v=1&x=KVu2DwXJp1l0-gmI3UYQPw Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WIProud.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203262512&p=1gw&v=1&x=g8Pey6N3nKIzp9KMHJVReQ Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet WTAJ-TV Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50203272412&p=1gw&v=1&x=Ejzt2LgJmduG38CwagpmkQ Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Media name/outlet User Walls Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202899863&p=1gw&v=1&x=bOyY_xo__x2lr4cZQW_9yg Persons Rajwanth Veluswamy Title BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations Media name/outlet MarketScreener.com Country/Territory United States Date 9/03/23 URL ct.moreover.com/?a=50202751819&p=1gw&v=1&x=CI8gM7cKwnv5BIOp1tfXZg Persons Rajwanth Veluswamy